黄芪注射液联合抗结核药对肺结核的治疗作用研究

A study on treating pulmonary tuberculosis with the Huangqi injection plus antituberculotic

目的:研究并分析使用黄芪注射液联合抗结核药治疗肺结核患者的治疗效果。方法:收集肺结核患者共87例,根据患者入院日期的单双号数分为对照组43例和观察组44例,对照组患者使用常规抗结核药物进行治疗,观察组在此基础上联合使用黄芪注射液,对两组患者的明显吸收率、痰菌转阴率、空洞闭合率以及不良反应发生率进行观察和对比。结果:观察组患者的明显吸收率显著高于对照组,观察组患者的痰菌转阴率显著高于对照组,观察组的不良反应发生率显著低于对照组,均P<0.05。结论:在肺结核患者的治疗过程中,联合使用黄芪注射液和抗结核药物能够获得显著疗效,且患者的不良反应发生率低,更加安全可靠,值得推广应用。

Objective: To study and analyze efficacy of the Huangqi injection plus antituberculotic on pulmonary tuberculosis. Methods: 87 cases were divided into the control group (43 cases) and the observation group (44 cases) according to the odd and even numbers. The control group was treated with conventional antituberculotic; the observation group was given the Huangqi injection more. The rate of obvious absorption, sputum negative conversion, cavity closure and adverse reaction were observed and compared. Results: The obvious absorption rate and sputum negative conversion were significantly higher; the adverse reactions rate was significantly lower in the observation group (P<0.05). Conclusion: The Huangqi injection plus antituberculotic on pulmonary tuberculosis shows a significant effect and fewer adverse reactions, is more safe and reliable, and worthy of popularization.